Previous studies have reported a significant proportion of patients with acromegaly continue to have biochemical control of disease after discontinuing SoC treatment for up to 12 months, as well as significant control of GH levels for patients switching from stable SoC treatment to placebo (29, 37, 41). This evidence concerns the gene GH1 and acromegaly.